SCHEMBL1198441

SCHEMBL1198441

O=C(O)c1cnn(Cc2ncc(-c3cccc(C(F)(F)F)c3)s2)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
NPC1 O15118 1/20 0.50
RAB9A P51151 1/20 0.50
EGLN1 Q9GZT9 2/20 0.47
ALDH1A1 P00352 2/20 0.43
KDM4E B2RXH2 1/20 0.43
LIPG Q9Y5X9 1/20 0.42
KDM4C Q9H3R0 1/20 0.42
HDAC6 Q9UBN7 3/20 0.42
KCNH2 Q12809 1/20 0.41
TRPV1 Q8NER1 1/20 0.41
ERCC5 P28715 1/20 0.41
FEN1 P39748 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
KMO O15229 2/20 0.41
POLB P06746 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
SRD5A2 P31213 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1198629 0.87 MEN1 (0.49) MEN1KMT2ANPC1RAB9AKDM4E
SCHEMBL12875720 0.85 HSD17B1 (0.47) MEN1KMT2ANPC1RAB9AEGLN1
SCHEMBL1198845 0.84 MEN1 (0.47) MEN1KMT2ANPC1RAB9AEGLN1
SCHEMBL1198884 0.84 MEN1 (0.48) MEN1KMT2ANPC1RAB9AEGLN1
SCHEMBL1198763 0.82 MEN1 (0.47) MEN1KMT2ANPC1RAB9AEGLN1
SCHEMBL1199084 0.82 EGLN1 (0.46) MEN1KMT2ANPC1RAB9AEGLN1
SCHEMBL1199569 0.82 MEN1 (0.46) MEN1KMT2ANPC1RAB9AEGLN1
SCHEMBL1198334 0.82 MEN1 (0.60) MEN1KMT2ANPC1RAB9AEGLN1
SCHEMBL1198292 0.81 ALDH1A1 (0.46) MEN1KMT2ANPC1RAB9AEGLN1
SCHEMBL1198947 0.81 KMO (0.44) MEN1KMT2ANPC1RAB9AEGLN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461348-B2 Heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-06-11 US disclosed
US-8461348-B2 Heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-06-11 US disclosed
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-02-03 US disclosed
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-02-03 US disclosed
EP-2264017-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2010-12-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF PDE3B, PDE5A, PDE2A MEN1 2661/4885KMT2A 3197/4885NPC1 3877/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.